The ophthalmologic drug developer has gone public three years after being founded by WuXi AppTec-backed 6 Dimensions Capital.
Ocumension Therapeutics, a China-based eye disease therapy developer backed by 6 Dimensions Capital – the healthcare investment firm formed by pharmaceutical company WuXi AppTec, went public on Tuesday.
The company raised about HK$1.55bn ($200m), issuing nearly 106 million shares on the Hong Kong Stock Exchange priced at HK$14.66 each. Its shares peaked at HK$42.50 on their first day of trading and closed at HK$31.70 today.
Founded in 2017 by 6 Dimensions Capital, Ocumension is developing treatments intended to meet significant…
